According to this GSK report. Relenza is a pipeline product.
''Product Development Pipeline'' February 2006
This document outlines GlaxoSmithKline’s drug development portfolio. The content of the portfolio will change over time as new compounds progress from research to development and from development to the market. Owing to the nature of the drug development process, it is not unusual for some compounds, especially those in early stages of investigation, to be terminated as they progress through development.''